ICH Q12 in Practice: Why PACMPs Belong in Your Phase 3 CMC Plan

Post-approval manufacturing changes are inevitable. Scale-up, site transfers, process optimizations, raw material substitutions: these are not exceptions in the lifecycle of a biologic or small molecule product. They are the

---

QTPP: The Foundation of Every Sound CMC Strategy

In pharmaceutical development, there is a concept that should sit at the very beginning of every program and continue to evolve throughout its lifecycle. Yet in practice, it is frequently

---

FDA’s Evolving Stance on Real-Time Release Testing (RTRT): Is Your QC Strategy Keeping Up?

Quality control in pharmaceutical manufacturing has long relied on a familiar routine: manufacture the batch, hold it, test the final product, and release it if it passes. But the FDA

---

ADC Tech Transfer: Why It’s Not Just a Standard Tech Transfer

The antibody-drug conjugate (ADC) space is moving fast. With over 15 FDA-approved ADCs as of 2025 and hundreds more in development, biotech companies are racing to scale manufacturing, qualifying new

---

ICH Q1 (Draft) – Stability

The Most Significant Overhaul of Pharmaceutical Stability Testing in Over Two Decades Stability testing is the backbone of pharmaceutical quality assurance. It tells us how a drug substance or drug

---

Navigating Phase-Appropriate Regulatory CMC Expectations: A Practical Comparison of FDA, EMA, Health Canada, and China Requirements

Introduction In pharmaceutical development, 'phase-appropriate CMC' has become both a guiding principle and a source of confusion. While the concept should facilitate efficient drug development, its interpretation varies significantly across

---

ICH M4Q(R2): The Evolution of Quality Module Submissions

Comparing M4Q(R1) and M4Q(R2) and Preparing for the Digital Future Introduction The ICH M4Q guideline has served as the backbone of quality module submissions since 2002, establishing a globally harmonized framework for

---